Experience. Innovation. A Team Dedicated to You.

In vitro disease models predicted advantages for use of 1/2-1/4 standard cytotoxic doses and selection of drugs each of which simultaneously interact with multiple drugs.

Targeted therapy added to cores of previously failed drugs has similarly produced responses of refractory pancreatic cancer.

The use of Bevacizumab (Bev) for ovarian cancer (OC) has been impeded by adverse events (AEs), long maintenance therapy (T) and tumor rebound. Eligibility, requirements and limits, as well as ideal time(s) and length of use remain unknowns. Drug interactions and algorithms offer testable solutions.